FranΓ§aisπ See the interactive version (live chart) β
For Harmony Biosciences Holdings, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 12% were profitable, average return -6% (96 calls). At 3 months: +0% average return (34% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Needham | 37 | 8% | -6% |
| Mizuho | 16 | 6% | -14% |
| Cantor Fitzgerald | 8 | 0% | -7% |
| Raymond James | 6 | 50% | +4% |
| Oppenheimer | 6 | 17% | -5% |
The analyst consensus on Harmony Biosciences Holdings, Inc. (HRMY) is "Buy" (15 bullish, 1 bearish calls over 12 months). This is not advice: historically, 12% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $50.00 (+25% vs $39.87), ranging from $34.00 to $55.00 (5 analysts).
Over 1 year, 12% of analyst targets on Harmony Biosciences Holdings, Inc. were profitable, for an average return of -6% (across 96 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $50.00 within 12 months, i.e. +25% vs the current price. The most bullish targets $55.00, the most cautious $34.00.
Note: analyst targets are 12-month (median $50.00, +25%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (12%), and the stock's past trajectory.
Detailed valuation data for Harmony Biosciences Holdings, Inc. is available in the interactive analysis.
π See the full interactive analysis of Harmony Biosciences Holdings, Inc. β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.